Pulmatrix, Inc. (NASDAQ: PULM) shares dived Thursday, a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation iSPERSE™ .
Pulmatrix Down On Q3 Results menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and issued a $10.00 price target on shares of Pulmatrix in a research report on Tuesday, August 15th. Check […]
StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report issued on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of Pulmatrix in a report on Tuesday, August 15th. Check Out Our […]
StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report report published on Friday. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright reaffirmed a buy rating and set a $10.00 price target on shares of Pulmatrix in a research note on Tuesday, August 15th. […]